389 related articles for article (PubMed ID: 30096243)
1. Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.
Osonoi T; Gouda M; Kubo M; Arakawa K; Hashimoto T; Abe M
Diabetes Technol Ther; 2018 Oct; 20(10):681-688. PubMed ID: 30096243
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
6. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Yoon SA; Han BG; Kim SG; Han SY; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang YH; Shin SH; Cha DR
Diabetes Obes Metab; 2017 Apr; 19(4):590-598. PubMed ID: 28019072
[TBL] [Abstract][Full Text] [Related]
8. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
9. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
[TBL] [Abstract][Full Text] [Related]
11. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
Takenaka T; Kishimoto M; Ohta M; Tomonaga O; Suzuki H
Diab Vasc Dis Res; 2017 May; 14(3):258-261. PubMed ID: 28467199
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Expert Opin Pharmacother; 2015; 16(11):1577-91. PubMed ID: 26104600
[TBL] [Abstract][Full Text] [Related]
14. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL
Clin J Am Soc Nephrol; 2023 Jun; 18(6):748-758. PubMed ID: 36999981
[TBL] [Abstract][Full Text] [Related]
15. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients.
Inagaki N; Harashima SI; Iijima H
Expert Opin Pharmacother; 2018 Jun; 19(8):895-908. PubMed ID: 29799286
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of canagliflozin in type 2 diabetes mellitus.
Perkovic V; Jardine M; Vijapurkar U; Meininger G
Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Iijima H; Kifuji T; Maruyama N; Inagaki N
Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urinary N-acetyl-beta-D-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus.
Bouvet BR; Paparella CV; Arriaga SM; Monje AL; Amarilla AM; Almará AM
Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):798-801. PubMed ID: 25465599
[TBL] [Abstract][Full Text] [Related]
20. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
